Learn more about the Science of p53
PMV Pharma is pioneering the discovery and development of p53 targeted small molecule drugs for the treatment of cancer.

PMV Pharmaceuticals develops small-molecule precision oncology therapies via selective p53 Y220C reactivation, with rezatapopt in trials for advanced solid tumors.
pmvpharma.comCrawled Nov 20, 2026
PMV Pharma is pioneering the discovery and development of p53 targeted small molecule drugs for the treatment of cancer.
PMV Pharmaceuticals provides access to investigational products targeting specific p53 mutations for cancer treatment.
The company’s therapeutic agents target specific p53 mutations to treat cancer with reduced off-target effects.
Working at PMV. Empowerment to challenge the status quo in an entrepreneurial environment is what it means to work at PMV.
The Management team for PMV Pharma. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.
PMV Pharma is developing first-in-class p53 regulators for the treatment of cancer. PMV Pharma combines unique biological understanding with pharmaceutical development focus.
PMV Pharmaceuticals releases its third-quarter 2026 financial results, detailing revenue, operational updates, and key corporate developments. The company highlights progress in its pipeline, including advancements in late-stage drug candidates. Management also outlines strategic initiatives aimed at expanding market reach and accelerating clinical trials.
PMV Pharmaceuticals presents late-breaking Phase 2 trial results for **Rezatapopt (PYNNACLE)** in a dedicated oral session at **ENA 2026**. The data highlights key efficacy and safety findings from the pivotal study, marking a milestone for the investigational therapy. Researchers share updated insights into patient responses and treatment protocols.
PMV Pharmaceuticals adds Matt Eckler, Ph.D., to its Board of Directors. Eckler holds over 20 years of experience in healthcare investing and scientific research, previously working at Samsara BioCapital, ArrowMark, and GMT Capital. His expertise spans public and private market investments in the healthcare sector.
PMV Pharmaceuticals launches an underwritten public offering of common stock and warrants, targeting investors for its precision oncology therapies focused on p53. The company, listed on Nasdaq as PMVP, aims to raise capital for advancing small molecule drug development in oncology. The offering includes pre-funded warrants for select investors.
PMV Pharmaceuticals releases its second-quarter 2026 financial results, detailing revenue growth and operational updates. The company highlights progress in its pipeline, including advancements in clinical-stage drug candidates. Leadership emphasizes strategic initiatives to accelerate development timelines while maintaining financial discipline.